1. Sarcopenia influences usage of reperfusion treatment in patients with pulmonary embolism aged 75 years and older
- Author
-
Karsten Keller, Volker H. Schmitt, Christoph Brochhausen, Omar Hahad, Martin Engelhardt, Christine Espinola-Klein, Thomas Münzel, Philipp Lurz, Stavros Konstantinides, and Lukas Hobohm
- Subjects
Pulmonary embolism ,Sarcopenia ,Clinical outcome ,Epidemiology ,Frailty ,Skeletal muscle impairment ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Although pulmonary embolism (PE) and sarcopenia are common diseases, only a few studies have assessed the impact of sarcopenia in PE on usage of reperfusion treatments in PE. Methods: All hospitalizations of PE patients aged ≥75 years 2005–2020 in Germany were included in this study and stratified for sarcopenia. Impact of sarcopenia on treatment procedures and adverse in-hospital events were investigated. Results: Overall, 576,364 hospitalizations of PE patients aged ≥75 years (median age 81.0 [78.0–85.0] years; 63.3 % females) were diagnosed in Germany during the observational period 2005–2020. Among these, 2357 (0.4 %) were coded with sarcopenia. PE patients with sarcopenia were in median 2 years older (83.0 [79.0–87.0] vs. 81.0 [78.0–85.0] years, P
- Published
- 2024
- Full Text
- View/download PDF